2025-04-11 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**0. Overview:**

Merck & Co Inc is a leading global biopharmaceutical company focused on the discovery, development, and manufacturing of innovative medicines and vaccines.

**1. Performance Comparison:**

Merck's cumulative return (7.87%) significantly underperformed the S&P 500 (VOO) return (65.78%) over the reviewed period. The difference is -57.9%, placing it at the 21.7th percentile of its historical range of performance relative to the S&P 500 (-80.6% to 23.9%). This indicates consistent underperformance against the broader market.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 5.0% | 58.4% | -24.0% | 0.0 | 109.0 |
| 2016-2018  | 42.0% | 66.6% | 24.0% | 0.1 | 152.5 |
| 2017-2019  | 40.0% | 66.6% | 11.0% | 0.2 | 186.5 |
| 2018-2020  | 19.0% | 66.6% | -6.0% | 0.4 | 173.1 |
| 2019-2021  | -1.0% | 65.6% | -55.0% | 0.5 | 176.1 |
| 2020-2022  | 13.0% | 69.3% | 7.0% | 0.5 | 263.1 |
| 2021-2023  | 35.0% | 69.3% | 19.0% | 0.3 | 265.8 |
| 2022-2024  | -6.0% | 69.3% | -23.0% | 0.3 | 249.1 |
| 2023-2025  | -45.0% | 70.3% | -59.0% | 0.2 | 195.9 |

The analysis shows inconsistent performance with fluctuating alpha and beta values, suggesting a lack of consistent outperformance relative to the market.  The negative alpha values in several periods highlight underperformance.


**2. Recent Price Movement:**

* **Closing Price:** $77.55
* **Previous Close:** $81.91
* **Change:** -$4.36 (Significant recent drop)
* **5-Day Moving Average:** $80.21
* **20-Day Moving Average:** $88.06
* **60-Day Moving Average:** $90.53

The price is below all three moving averages, indicating a downtrend.  The significant daily price drop (-5.32) is a considerable negative factor.

**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4292 (Medium Risk)
* **RSI:** 20.39 (Oversold territory, suggesting potential bounce but not guaranteeing it)
* **PPO:** -1.38 (Bearish signal)
* **Relative Strength Change (20-day):** -3.0 (Short-term downtrend)
* **Expected Return:** -35.3% (Significant negative expectation relative to the market over the long term).  This is likely reflecting the underperformance already observed and the market's negative outlook on the company.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-11-06 | 1.25 | $16.66 B      |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2023-11-03 | 1.87 | $15.96 B      |
| 2024-11-06 | 1.87 | $15.96 B      | *(Duplicate Entry, likely an error)*

Earnings show volatility, with a significant drop in EPS in the most recent quarter (November 2024).  Revenue remains relatively consistent.  The duplicate entry needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |
| 2023-12-31 | $14.63B   | 73.26%        |

Revenue is relatively stable, though showing slight decline in the most recent quarter. Profit margins are high and relatively stable, suggesting solid profitability.

**Capital and Profitability:**

| Quarter | Equity     | ROE          |
|---------|------------|--------------|
| 2024-12-31 | $46.31B   | 8.08%        |
| 2024-09-30 | $44.50B   | 7.09%        |
| 2024-06-30 | $43.58B   | 12.52%       |
| 2024-03-31 | $40.36B   | 11.80%       |
| 2023-12-31 | $37.58B   | -3.26%       |

Equity is growing, but ROE shows some volatility, with a significant negative value in 2023.


**6. Overall Analysis:**

Merck (MRK) is currently exhibiting signs of significant underperformance compared to the S&P 500.  While profitability remains strong, recent earnings show declining EPS and the stock price is experiencing a downtrend. Technical indicators suggest an oversold condition, but also a bearish outlook. The negative expected return and consistent underperformance against the market raise serious concerns.  Further investigation into the reasons for the recent EPS decline and the overall underperformance is crucial before considering any investment.  The high profit margins are a positive sign, however, the recent downward trends in various metrics significantly outweigh this positive.  More data and a deeper fundamental analysis are needed to determine a suitable investment strategy.
